Cat. No. 2442
Chemical Name: 5,6-bis[(4-Fluorophenyl)amino]-1H-i
Biological ActivitySelective inhibitor of PKCβII (IC50 values are 0.41 and 3.8 μM for PKCβII and PKCβI respectively). Also inhibits prionogenic Sup35 fibrillization (IC50 ~ 3.4 μM) and inhibits de novo Aβ42 assembly in vitro.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Wang et al (2008) Direct and selective elimination of specific prions and amyloids by 4,5-dianilinophthalimide and analogs. Proc.Natl.Acad.Sci.USA 105 7159.
Kouroedov et al (2004) Selective inhibition of protein kinase Cβ2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 110 91. PMID: 15210597.
If you know of a relevant reference for CGP 53353 please let us know.
Citations are publications that use Tocris products. Selected citations for CGP 53353 include:
Liu et al (2014) PKCβII acts downstream of chemoattractant receptors and mTORC2 to regulate cAMP production and myosin II activity in neutrophils. Mol Biol Cell 25 1446. PMID: 24600048.
He et al (2011) Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells. J Neurosci 18 39. PMID: 21672207.
Do you know of a great paper that uses CGP 53353 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: CGP 53353, supplier, Selective, inhibitors, inhibits, PKCbetaII, de, novo, Aβ4, β42, beta42, assesmbly, PKC, PKM, Protein, Kinase, C, Kinases, b-amyloid, β-Amyloid, beta-Amyloid, Precursor, APP, Secretase, beta, Peptides, prionogenic, Sup35, fibrillization, CGP53353, amyloidbeta, amyloidb, amyloidβ, Tocris Bioscience, Protein Kinase C Inhibitor products
Find multiple products by catalog number
New Products in this Area
Inhibitor of Clk and DYRK kinasesEverolimus
mTOR inhibitor;immunosuppressantPKI (5-24)
High affinity PKA inhibitorTDZD 8
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitorLTURM 34
Potent DNA-PK inhibitorMLi-2
Potent and selective LRRK2 inhibitorLTURM 36
PI 3-kinase δ inhibitorPI 3065
Potent and selective PI 3-kinase p110δ inhibitor
April 22 - 26, 2017
Chicago, IL, USA